secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001193805-25-001175
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q2 revenue $28.3M (-43% YoY); net loss narrows to $9.2M; CF data due Sep
--------------------------------------------------------------------------------

- Revenue fell 43% YoY to $28.3M, driven by lower CSL collaboration activity and KOSTAIVE amortization.
- Net loss improved to $9.2M ($0.34 loss per share) from $17.2M loss in Q2 2024.
- Operating expenses dropped to $39.9M from $71.0M, mainly on lower KOSTAIVE and flu program costs.
- Cash and restricted cash $253.4M, extended runway into 2028.
- ARCT-032 CF Phase 2 interim data for 9 participants due Sep 2025; KOSTAIVE UK MAA decision expected Sep 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/0001193805-25-001175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/e664773_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-001175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer